97029 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Immunoglobulin superfamily
COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES
#302RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2
#303PROTEIN COMPRISING AT LEAST ONE REGULATORY T CELL ACTIVATING EPITOPE
#304USE OF CD83 IN COMBINATION THERAPIES
#305USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
#306COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF
#307CAR T CELL THERAPIES WITH ENHANCED EFFICACY
#308ANTI-PACAP ANTIBODIES AND USES THEREOF
#309POLYPEPTIDE AFFINITY LIGANDS AND METHODS OF USING
#310NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
#311CHIMERIC FUSIONS BETWEEN C4-BINDING PROTEIN C-TERMINAL SEGMENT AND ANGIOPOIETIN-1 FIBRINOGEN-LIKE DOMAIN AS ANGIOPOIETIN MIMETICS AND TIE2 AGONISTS TO TREAT VASCULAR DISEASES
#312COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE
#313POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF
#314CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY
#315Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#316CHIMERIC ANTIGEN RECEPTORS FOR REMOVAL OF AMYLOID
#317TAFA4 POLYPEPTIDE OR POLYNUCLEOTIDE FOR TREATING INFLAMMATORY DISEASE
#318Compounds for treatment of eye diseases associated with excessive vascularisation
#319CTL PEPTIDE EPITOPES AND ANTIGEN-SPECIFIC T CELLS, METHODS FOR THEIR DISCOVERY, AND USES THEREOF
#320CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF
#321Chimeric antigen receptors targeting B-cell maturation antigen
#322TGFBR2-BASED CHIMERIC PROTEINS
#323NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS
#324SECRETABLE PROTEIN INDUCED IMMUNE TOLERIZATION AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
#325Chimeric antigen receptors targeting B-cell maturation antigen
#326BLOCKING CHIMERIC ANTIGEN RECEPTORS FOR PREVENTION OF UNDESIRED ACTIVATION OF EFFECTOR AND REGULATORY IMMUNE CELLS
#327NUCLEIC ACID ENCODING LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR
#328COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS
#329HIGH AVIDITY ANTIGEN RECOGNIZING CONSTRUCTS
#330PROTEIN BLOCKING ASSEMBLY AND METHODS OF MAKING AND USING
#331IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#332BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
#333HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES
#334Chimeric antigen receptors targeting B-cell maturation antigen
#335Antitumor peptide and use thereof
#336B-CELL ANTIBODY RECEPTOR AND USE THEREOF
#337PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY
#338Platforms, compositions, and methods for therapeutic delivery
#339ENGINEERED T CELL RECEPTORS AND USES THEREOF
#340IMMORTALIZED CARDIAC STEM CELLS FOR CARDIAC REPAIR
#341FUSION PROTEINS OF PD-1 AND 4-1BB
#342RECEPTOR-BASED ANTAGONISTS OF THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY
#343Macrophage CAR (MOTO-CAR) In Immunotherapy
#344Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
#345Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#346INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
#347ANTI-GLYPICAN-1-IMMUNIZING ANTIGEN RECEPTOR
#348Lentivirus packaging system, lentivirus produced by the same, cell transduced by the lentivirus, method for improving lentivirus production in a host cell, and method of using the cell for treating cancer
#349CHIMERIC ANTIGEN RECEPTOR ANTI-INFLAMMATORY CELLS AND METHODS OF USE
#350COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#351CD200 inhibitors and methods of use thereof
#352SIRPalpha-SILENCED NATURAL KILLER (NK) CELLS
#353TREATMENT METHODS USING ADENOVIRUS
#354METHODS OF B CELL EXPANSION FOR USE IN CELL THERAPY
#355Methods and compositions for modulating CAR-T activity
#356AAV VECTORS WITH MYELIN PROTEIN ZERO PROMOTER AND USES THEREOF FOR TREATING SCHWANN CELL-ASSOCIATED DISEASES LIKE CHARCOT-MARIE-TOOTH DISEASE
#357POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION
#358TARGETED CANCER THERAPY
#359INDUCTION OF ARTERIAL-TYPE OF HEMOGENIC ENDOTHELIUM (AHE) AND ENHANCEMENT OF T CELL PRODUCTION FROM PSCS THROUGH OVEREXPRESSION OF ETS FACTORS OR MODULATING MAPK/ERK SIGNALLING PATHWAYS
#360CHIMERIC PROTEINS IN AUTOIMMUNITY
#361CHIMERIC INHIBITORY RECEPTOR
#362STERIC EPITOPE OF CEACAM1, AND ANTI-CEACAM1 ANTIBODY, OR FRAGMENT THEREOF, THAT SPECIFICALLY BINDS TO SAME
#363LILRB1-based chimeric antigen receptor
#364ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
#365MICROVASCULAR BLOOD FLOW DECREASING AGENT AND USE THEREOF
#366Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
#367CELL-TYPE SELECTIVE IMMUNOPROTECTION OF CELLS
#368Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#369CHIMERIC ANTIGEN RECEPTORS TARGETING HER2
#370Compositions for increasing half-life of a therapeutic agent in felines and methods of use
#371COMPOSITIONS AND METHODS OF ACETYLCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS
#372Methods and compositions for modulating CAR-T activity
#373COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS
#374AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#375DHFR tunable protein regulation
#376AFFINITY MATURATED T CELL RECEPTORS AND USE THEREOF
#377MULTIMERS FOR REDUCING THE INTERFERENCE OF DRUGS THAT BIND CD47 IN SEROLOGICAL ASSAYS
#378T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3
#379MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
#380IMMUNOSUPPRESSIVE GLYCOFORMS OF SOLUBLE CD52
#381CELL SURFACE COUPLING OF NANOPARTICLES
#382GENETICALLY MODIFIED IMMUNE CELL, PREPARATION METHOD THEREFOR, AND APPLICATION
#383METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF
#384Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
#385Methods of classifying response to immunotherapy for cancer
#386PD-1-CD28 FUSION PROTEINS AND THEIR USE IN MEDICINE
#387DELIVERY VECTORS AND PARTICLES FOR EXPRESSING CHIMERIC RECEPTORS AND METHODS OF USING THE SAME
#388LILRB1-based chimeric antigen receptor
#389METHOD FOR PRODUCING IMMUNOCYTES, AND USE THEREOF
#390ENGINEERED GAMMA DELTA T-CELLS
#391LILRB1-based chimeric antigen receptor
#392METHODS OF MODULATING CD160 FUNCTION IN THE ANTIGEN-SPECIFIC IMMUNE CELL AND USES THEREOF
#393GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#394STABILIZED EXTRACELLULAR DOMAIN OF CD19
#395GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#396SOLUBLE THY-1 COMPOSITIONS AND USE THEREOF TO TREAT OR REVERSE FIBROSIS
#397CELLS, COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE FUNCTION
#398T cell receptors
#399MODIFIED CELLS AND METHODS OF THERAPY
#400METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS
#401RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof
#402Immune cell compositions and methods of use
#403Nucleic acid construct
#404CHIMERIC ANTIGEN RECEPTORS
#405TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
#406Engineered PD-1 variants
#407Chimeric engulfment receptor molecules
#408PHARMACEUTICAL COMPOSITION OR FOOD COMPOSITION, AND METHOD FOR ASSESSING EFFECT OF ACTIVE INGREDIENT IN VIVO
#409mRNA combination therapy for the treatment of cancer
#410Protein M fusion proteins and uses
#411CANCER ANTIGEN TARGETS AND USES THEREOF
#412Expression of novel cell tags
#413D-domain containing polypeptides and uses thereof
#414COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF HER2+ CANCERS
#415POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
#416METHODS OF REDUCING LIVER PD-1-EXPRESSING CD8+ T CELLS USING PD-1 FC FUSION PROTEINS THAT BIND FC RECEPTORS
#417A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)
#418METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND USE THEREOF
#419Preparation and Application of Soluble Tim-3 Recombinant Protein and Mutant Protein Thereof
#420INHIBITORY CHIMERIC ANTIGEN RECEPTORS
#421PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF
#422IMMUNOMODULATORY CELLS AND USES THEREOF
#423IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#424Compositions for increasing half-life of a therapeutic agent in felines and methods of use
#425Treatment of renal cell carcinoma
#426CEACAM1 MEDIATED PROTECTIVE IMMUNITY
#427CEACAM1 BASED CANCER THERAPY AND DIAGNOSIS
#428Immunomodulatory fusion proteins and uses thereof
#429CANCER ANTIGEN SPECIFIC CYTOTOXIC T CELL
#430MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATING A SIGLEC-MEDIATED DISORDER
#431SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#432Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#433Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
#434TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
#435CHIMERIC SIGNAL PEPTIDES FOR PROTEIN PRODUCTION
#436BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#437RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2
#438Artificial synapses
#439Fusion proteins comprising extracellular domain of human CD22
#440Non-human animals having a humanized lymphocyte-activation gene 3
#441Primers for immune repertoire profiling
#442CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
#443Methods and materials for treating cancer
#444DECOY POLYPEPTIDES
#445EXTRACELLULAR VESICLES FOR TARGETED THERAPIES AGAINST MYELOID-DERIVED SUPPRESSOR CELLS
#446Expression of novel cell tags
#447GENOMIC ENGINEERING OF PLURIPOTENT CELLS
#448MODULATION OF APOPTOSIS SUSCEPTIBLE CELLS
#449Compounds for treatment of eye diseases associated with excessive vascularisation
#450ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
#451NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
#452CD47 blockade with PARP inhibition for disease treatment
#453POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#454THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS
#455USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR
#456Heterotandem bicyclic peptide complexes
#457ENHANCED PRODUCTION OF IMMUNOGLOBULINS
#458TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
#459Siglec-9 ECD fusion molecules
#460Fine nano-sized medicinal agent and use thereof
#461CHIMERIC RECEPTORS TO STEAP1 AND METHODS OF USE THEREOF
#462Materials and methods for treatment with oncolytic viruses and modified CAR T cells
#463GENETIC ENGNEERING OF B CELL RECEPTORS AND USES THEREOF IN ANTIGEN-INDUCED ANTIBODY SECRETION
#464Anti-TrkB agonist antibodies binding to D1 domain of TrkB
#465TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT
#466Cell surface coupling of nanoparticles
#467Modified cells and methods of therapy
#468ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF
#469POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION
#470Long-Acting Recombinant GLP1-Fc-CD47 Protein and Preparation and Use Thereof
#471Non-human animals having a humanized signal-regulatory protein gene
#472CD47 blockade with radiation therapy
#473Peptide suppressing binding of CTLA4 to B7 proteins, and use thereof
#474T CELL REGULATION
#475LILRB1-based chimeric antigen receptor
#476METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#477Recombinant ROBO2 proteins, compositions, methods and uses thereof
#478Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#479Reagents and methods for treating cancer and autoimmune disease
#480TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS
#481GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
#482Inducible Cell Receptors for Cell-Based Therapeutics
#483RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses Thereof
#484Lyophilized preparation
#485CELL
#486ADAPTER-BASED RETROVIRAL VECTOR SYSTEM FOR THE SELECTIVE TRANSDUCTION OF TARGET CELLS
#487COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINS
#488Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies
#489TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
#490CD19 and CD22 chimeric antigen receptors and uses thereof
#491UNIVERSAL DONOR STEM CELLS AND RELATED METHODS
#492Peptide bound to PD-L1 and use thereof
#493ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
#494Mouse having a humanized cluster of differentiation 47 gene
#495ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF
#496CELL
#497Methods of inhibiting integrin α9β1 activity
#498VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#499METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY
#500VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
#501COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
#502Chimeric antigen receptors targeting b-cell maturation antigen
#503CD200 inhibitors and methods of use thereof
#504Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
#505Chimeric antigen receptors targeting B-cell maturation antigen
#506Chimeric antigen receptors targeting B-cell maturation antigen
#507THERAPEUTIC EXTRACELLULAR VESICLES
#508Methods of Sequencing, Determining, Pairing, and Validating Therapeutic Agents and Disease Specific Antigens
#509Reducing immune tolerance induced by PD-L1
#510INHIBITION OF INNATE IMMUNE RESPONSE
#511Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#512CD19 variants
#513Compositions and methods for immunooncology
#514Constructs having a SIRP-alpha domain or variant thereof
#515Methods of treating aging-related disorders
#516Modulation of SLAMF6 splice variants for cancer therapy
#517Affinity ligands for antibody Fc region
#518Treatment of infection by human enterovirus D68
#519Genetically modified non-human animal with human or chimeric LAG3
#520Anti-TIGIT antibody and use thereof
#521High affinity PD-1 agents and methods of use
#522VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#523Guidance and Navigation Control proteins and method of making and using thereof
#524NKG2D CHIMERIC ANTIGEN RECEPTORS
#525Cellular immunotherapy compositions and uses thereof
#526LENTIVIRAL VECTORS FOR REGULATED EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR MOLECULE
#527Use of ICOS-based cars to enhance antitumor activity and car persistence
#528METHODS OF MAKING AND USING GUIDANCE AND NAVIGATION CONTROL PROTEINS
#529METHODS FOR PREVENTING FUNGAL INFECTIONS
#530Compositions and methods for CAR T cell therapy
#531Compositions and methods for inhibiting CD279 interactions
#532Tim protein-bound carrier, methods for obtaining, removing and detecting extracellular membrane vesicles and viruses using said carrier, and kit including said carrier
#533Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
#534UNIVERSAL ANTIGEN PRESENTING CELLS AND USES THEREOF
#535PVRIG polypeptides and methods of treatment
#536METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
#537Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#538METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
#539Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway
#540Nucleic acids encoding chimeric receptor comprising NKP30 receptor and CD28 and CD3 zeta domains and human T cell containing
#541Bifunctional fusion protein targeting CD47 and PD-L1
#542Intracellular genomic transplant and methods of therapy
#543Compositions and methods useful in promoting milk production
#544TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
#545Combined preparations for the treatment of cancer
#546Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
#547Compositions and methods for immunotherapy
#548Compositions and methods for the treatment of immune related diseases
#549Gene therapies for lysosomal disorders
#550Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
#551Chimeric engulfment receptor molecules and methods of use
#552Intracellular genomic transplant and methods of therapy
#553INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
#554Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
#555USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION
#556TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
#557Tumor infiltrating lymphocytes and methods of therapy
#558Targeted protein degradation
#559Method for treating cancer with c-kit antibodies
#560Gene therapies for lysosomal disorders
#561Gene therapies for lysosomal disorders
#562Immunotherapeutic method for treating lung cancer by administering a polypeptide comprising an epitope of hZP3
#563Coiled coil immunoglobulin fusion proteins and compositions thereof
#564SIRP-gamma polypeptide compositions and treatment of cancer
#565SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#566Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#567Compositions and methods for treatment of cancer
#568Synthetic biology-based ADCC technology
#569Chimeric Antigen Receptor
#570Constructs having a SIRP-α domain or variant thereof
#571TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
#572Preparation of therapeutic exosomes using membrane proteins
#573METHODS OF TREATMENT USING DECITABINE AND A CD123-TARGETED THERAPY
#574Integral membrane protein display on poxvirus extracellular enveloped virions
#575Methods of classifying response to immunotherapy for cancer
#576Screening assays, modulators and modulation of activation of Receptor for Advanced Glycation End-products (RAGE)
#577TREM2 MUTANTS RESISTANT TO SHEDDASE CLEAVAGE
#578CHIMERIC RECEPTORS
#579IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS
#580Human PD1 peptide vaccines and uses thereof
#581Cancer antigen specific cytotoxic T cell
#582Non-human animals having a humanized signal-regulatory protein gene
#583Cancer antigen targets and uses thereof
#584Humanized anti-PACAP antibodies
#585Humanized anti-PACAP antibodies
#586DHFR tunable protein regulation
#587Humanized anti-PACAP antibodies
#588NETRIN- 1 AND DEPENDENCE RECEPTOR PROTEINS AND METHOD OF USE
#589Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#590Oncolytic viral delivery of therapeutic polypeptides
#591Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
#592Genetic engineering of macrophages for immunotherapy
#593Methods and compositions for modulating cytotoxic lymphocyte activity
#594Antitumor peptide and use thereof
#595Hematopoietic stem cell expansion method
#596T-cell modulatory multimeric polypeptides and methods of use thereof
#597RAGE PROTEINS FOR THE TREATMENT OF FIBROSIS AND DNA DAMAGE MEDIATED DISEASES
#598TREATING INFLAMMATION WITH SOLUBLE HYBRID FCGAMMA RECEPTORS
#599PANCREATIC CANCER TARGETS AND USES THEREOF
#600RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof